Trial Profile
A Phase II, Single Arm Study of Atezolizumab + Bevacizumab in Women With Advanced, Recurrent or Persistent Endometrial Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- 04 Dec 2023 Planned number of patients changed from 55 to 110.
- 04 Dec 2023 Planned End Date changed from 25 May 2024 to 1 May 2025.
- 04 Dec 2023 Planned primary completion date changed from 31 Aug 2023 to 31 Aug 2024.